SCHEMBL23908001

SCHEMBL23908001

CSc1nc(OCC(=O)NC23CC4CC(CC(C4)C2)C3)cc(OC(C)C)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.43
HPGD P15428 2/20 0.43
TSHR P16473 2/20 0.43
KMT2A Q03164 4/20 0.40
PTPRC P08575 1/20 0.39
PTPN1 P18031 1/20 0.39
PTPN11 Q06124 1/20 0.39
PTPN13 Q12923 1/20 0.39
PTPN22 Q9Y2R2 1/20 0.39
MEN1 O00255 3/20 0.39
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 1/20 0.39
THRB P10828 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAA P10253 1/20 0.39
EPHX2 P34913 1/20 0.39
OPRK1 P41145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23908016 0.91 ALDH1A1 (0.45) ALDH1A1HPGDTSHRKMT2APTPRC
SCHEMBL28978608 0.89 ALDH1A1 (0.41) ALDH1A1HPGDTSHRKMT2APTPRC
SCHEMBL23884202 0.88 ALDH1A1 (0.46) ALDH1A1HPGDTSHRKMT2APTPRC
SCHEMBL23884283 0.86 ALDH1A1 (0.46) ALDH1A1HPGDTSHRKMT2APTPRC
SCHEMBL23908017 0.86 ALDH1A1 (0.42) ALDH1A1HPGDTSHRKMT2APTPRC
SCHEMBL23908012 0.85 ALDH1A1 (0.43) ALDH1A1HPGDTSHRKMT2APTPRC
SCHEMBL23908018 0.85 ATM (0.45) ALDH1A1HPGDTSHRKMT2APTPRC
SCHEMBL23907976 0.85 ALDH1A1 (0.43) ALDH1A1HPGDTSHRKMT2APTPRC
SCHEMBL23908009 0.85 ALDH1A1 (0.41) ALDH1A1HPGDTSHRKMT2APTPRC
SCHEMBL30361616 0.85 ALDH1A1 (0.41) ALDH1A1HPGDTSHRKMT2APTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11932626-B2 2-pyrimidone analogs as potent antiviral agents against Alphaviruses SOUTHERN RESEARCH INSTITUTE (US) 2024-03-19 US disclosed
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses OREGON HEALTH AND SCIENCE UNIVERSITY 2023-04-20 US disclosed
CN-115916175-A Novel 2-pyrimidinone analogs as potent antiviral agents against alphaviruses 南方研究院 2023-04-04 CN disclosed
US-11566019-B2 2-pyrimidone analogs as potent antiviral agents against alphaviruses SOUTHERN RESEARCH INSTITUTE (US) 2023-01-31 US disclosed
US-20220177452-A9 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-06-09 US disclosed
US-20210317106-A1 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses SOUTHERN RES INST (US) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317106-A1 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 492/4885HPGD 1775/4885TSHR 4534/4885
US-11566019-B2 2-pyrimidone analogs as potent antiviral agents against alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 492/4885HPGD 1775/4885TSHR 4534/4885
US-11932626-B2 2-pyrimidone analogs as potent antiviral agents against Alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 492/4885HPGD 1775/4885TSHR 4534/4885
US-20220177452-A9 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 492/4885HPGD 1775/4885TSHR 4534/4885
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS ALDH1A1 589/4885HPGD 2020/4885TSHR 4519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.